Table 1.
Patient Demographic, Clinical, and Pathologic Characteristics by Treatment Arm
| Characteristic | Arm I: CIMRT (n = 152) |
Arm II: HIMRT (n = 151) |
P* | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age, years | .436 | ||||
| 45 to 54 | 13 | 8.6 | 10 | 6.6 | |
| 55 to 64 | 47 | 30.9 | 43 | 28.5 | |
| 65 to 74 | 62 | 40.8 | 75 | 49.7 | |
| ≥ 75 | 30 | 19.7 | 23 | 15.2 | |
| Mean | 66.9 | 66.7 | |||
| SD | 8.4 | 7.6 | |||
| T category | .767 | ||||
| T1 | 59 | 38.8 | 61 | 40.4 | |
| T2 | 77 | 50.7 | 71 | 47.0 | |
| T3 | 16 | 10.5 | 19 | 12.6 | |
| GS | .960 | ||||
| 6 | 51 | 33.5 | 53 | 35.1 | |
| 7 | 72 | 47.4 | 70 | 46.4 | |
| 8 to 10† | 29 | 19.1 | 28 | 18.5 | |
| Pretreatment PSA, ng/mL | .889 | ||||
| < 10 | 99 | 65.1 | 95 | 62.9 | |
| 10 to 20 | 40 | 26.3 | 41 | 27.2 | |
| > 20 | 13 | 8.6 | 15 | 9.9 | |
| Pretreatment biopsy PPT, % | .679 | ||||
| ≤ 20 | 41 | 27.7 | 48 | 32.0 | |
| > 20 | 107 | 72.3 | 102 | 68.0 | |
| Unknown | 4 | 1 | |||
| Protocol risk group and planned duration of ADT | .701 | ||||
| Intermediate; none‡ | 81 | 53.3 | 83 | 55.0 | |
| Intermediate; short term§ | 20 | 13.2 | 15 | 9.9 | |
| High; long term‖ | 51 | 33.5 | 53 | 35.1 | |
Abbreviations: ADT, androgen deprivation therapy; CIMRT, conventional fractionated intensity-modulated radiotherapy; GS, Gleason score; HIMRT, hypofractionated intensity-modulated radiotherapy; NCCN, National Comprehensive Cancer Network; PPT, percent positive tissue; PSA, prostate-specific antigen; SD, standard deviation.
Fisher's exact test.
Gleason grade 5, as a component of GS 8 to 10, was seen in five and 10 patients in CIMRT and HIMRT arms, respectively, and there was no statistical difference.
Patients who did not receive ADT were intermediate risk per protocol classification, including 45 with favorable risk per NCCN criteria and one patient later determined to have GS 8 (high risk) on basis of biopsy review.
Short-term ADT patents were intermediate risk per protocol and included one favorable risk per NCCN criteria.
Long-term ADT patients were high risk per protocol, including 18 (CIMRT, seven; HIMRT, 11) GS7 patients with ≥ four positive cores and no other high risk factors (17 intermediate risk and one favorable per NCCN criteria).